Grown Rogue International (GRUSF) Cash from Investing Activities (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Cash from Investing Activities came in at -$2.9 million in Q1 2026, down 761.12% year-on-year from $434808.6 in Q1 2025, and down 100.0% quarter-over-quarter from $1955.8 billion in Q4 2025.
Grown Rogue International (GRUSF) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Grown Rogue International's Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$2.9 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 761.12% year-over-year to -$2.9 million in Q1 2026; TTM through Mar 2026 was $1955.8 billion, a 28569526.18% increase from a year earlier, with the FY2025 full-year figure at -$6.9 million, up 23.4% from the prior year.
- Cash from Investing Activities fell to -$2.9 million in Q1 2026 per GRUSF's latest filing, from $1955.8 billion in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1955.8 billion in Q4 2025 and bottomed at -$2.9 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$1.4 million (2023), against an average of $163.0 billion.
- Across the five-year window, Cash from Investing Activities surged 103863188.84% in 2025 and tumbled 761.12% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$455557.1 in 2022, then tumbled by 361.53% to -$2.1 million in 2023, then grew by 10.44% to -$1.9 million in 2024, then surged by 103863188.84% to $1955.8 billion in 2025, then sank by 100.0% to -$2.9 million in 2026.
- Per Business Quant, the three latest GRUSF Cash from Investing Activities figures stand at -$2.9 million (Q1 2026), $1955.8 billion (Q4 2025), and -$333822.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 743.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | -2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | 1,955.77 Bn |
| Dec 31, 2025 | 1,955.77 Bn |
| Mar 31, 2025 | -333,822.00 |
| Mar 31, 2025 | -333,822.00 |
| Dec 31, 2024 | -1.88 Mn |
| Dec 31, 2024 | -1.88 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Oct 31, 2023 | -2.10 Mn |
| Oct 31, 2023 | -2.10 Mn |
| Jul 31, 2023 | -910,381.00 |
| Jul 31, 2023 | -910,381.00 |
| Apr 30, 2023 | -428,955.00 |
| Apr 30, 2023 | -428,955.00 |